TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Sponsor: Dana-Farber Cancer Institute · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 37 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT04421560 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04421560 Rescue Dossier →